Screener
AbCellera Biologics Inc. ABCL Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
FAQ
- What is AbCellera Biologics Inc.'s cash & equivalents?
- AbCellera Biologics Inc. (ABCL) reported cash & equivalents of $145.07M in Q2 2026.
- How has AbCellera Biologics Inc.'s cash & equivalents changed year-over-year?
- AbCellera Biologics Inc.'s cash & equivalents increased by 23.5% year-over-year, from $117.44M to $145.07M.
- What is the long-term trend for AbCellera Biologics Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s cash & equivalents has grown at a -26.4% compound annual growth rate (CAGR), from $594.12M to $128.51M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about AbCellera Biologics Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude